AI Assistant
Blog
Pricing
Log In
Sign Up
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
